The University of Chicago Header Logo

Connection

Richard A. Larson to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Richard A. Larson
Connection Strength
10.114
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  1. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
    View in: PubMed
    Score: 0.612
  2. Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790.
    View in: PubMed
    Score: 0.523
  3. Is there a best TKI for chronic phase CML? Blood. 2015 Nov 19; 126(21):2370-5.
    View in: PubMed
    Score: 0.493
  4. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015 Apr; 94 Suppl 2:S249-57.
    View in: PubMed
    Score: 0.472
  5. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug; 70(2):345-50.
    View in: PubMed
    Score: 0.387
  6. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct; 26(10):2197-203.
    View in: PubMed
    Score: 0.387
  7. CML: live long and prosper. Blood. 2011 Oct 27; 118(17):4499-500.
    View in: PubMed
    Score: 0.372
  8. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leuk Lymphoma. 2009 Jun; 50(6):868-70.
    View in: PubMed
    Score: 0.315
  9. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Clin Adv Hematol Oncol. 2009 Feb; 7(2):S3-5.
    View in: PubMed
    Score: 0.308
  10. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8.
    View in: PubMed
    Score: 0.296
  11. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res. 2004 May; 28(5):537-40.
    View in: PubMed
    Score: 0.222
  12. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023 Dec 01; 6(12):e2347950.
    View in: PubMed
    Score: 0.215
  13. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578.
    View in: PubMed
    Score: 0.208
  14. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9.
    View in: PubMed
    Score: 0.206
  15. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48.
    View in: PubMed
    Score: 0.202
  16. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
    View in: PubMed
    Score: 0.201
  17. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022 11 01; 107(11):2641-2649.
    View in: PubMed
    Score: 0.200
  18. Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. Am J Hematol. 2022 08; 97(8):E296-E298.
    View in: PubMed
    Score: 0.194
  19. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 01 11; 114(1):160-164.
    View in: PubMed
    Score: 0.189
  20. Economics influences therapy decisions in chronic myeloid leukaemia: should it? J Cancer Res Clin Oncol. 2021 Dec; 147(12):3693-3698.
    View in: PubMed
    Score: 0.180
  21. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453.
    View in: PubMed
    Score: 0.176
  22. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):42-50.
    View in: PubMed
    Score: 0.176
  23. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984.
    View in: PubMed
    Score: 0.166
  24. Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 2019 05; 80:40-42.
    View in: PubMed
    Score: 0.156
  25. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 04 02; 18(1):359.
    View in: PubMed
    Score: 0.145
  26. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol. 1998 Apr; 16(4):1498-504.
    View in: PubMed
    Score: 0.145
  27. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 03 09; 376(10):917-927.
    View in: PubMed
    Score: 0.135
  28. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.
    View in: PubMed
    Score: 0.133
  29. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.126
  30. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 05; 30(5):1044-54.
    View in: PubMed
    Score: 0.125
  31. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
    View in: PubMed
    Score: 0.116
  32. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
    View in: PubMed
    Score: 0.113
  33. Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. J Clin Oncol. 2016 Feb 20; 34(6):e46-8.
    View in: PubMed
    Score: 0.112
  34. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27; 123(9):1353-60.
    View in: PubMed
    Score: 0.108
  35. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
    View in: PubMed
    Score: 0.104
  36. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8.
    View in: PubMed
    Score: 0.102
  37. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.100
  38. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62.
    View in: PubMed
    Score: 0.094
  39. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
    View in: PubMed
    Score: 0.092
  40. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11; 116(19):3758-65.
    View in: PubMed
    Score: 0.085
  41. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51.
    View in: PubMed
    Score: 0.081
  42. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75.
    View in: PubMed
    Score: 0.080
  43. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9.
    View in: PubMed
    Score: 0.079
  44. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun; 23(6):1054-61.
    View in: PubMed
    Score: 0.078
  45. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.077
  46. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
    View in: PubMed
    Score: 0.074
  47. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View in: PubMed
    Score: 0.073
  48. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.072
  49. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.072
  50. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15; 109(10):4143-50.
    View in: PubMed
    Score: 0.067
  51. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17.
    View in: PubMed
    Score: 0.066
  52. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20.
    View in: PubMed
    Score: 0.064
  53. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103.
    View in: PubMed
    Score: 0.064
  54. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84.
    View in: PubMed
    Score: 0.063
  55. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol. 2004 Jul; 25(1):143-51.
    View in: PubMed
    Score: 0.056
  56. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6.
    View in: PubMed
    Score: 0.054
  57. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9.
    View in: PubMed
    Score: 0.048
  58. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000 Mar; 18(6):1301-8.
    View in: PubMed
    Score: 0.041
  59. Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive. Leukemia. 1998 Feb; 12(2):233-7.
    View in: PubMed
    Score: 0.036
  60. High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):391-6.
    View in: PubMed
    Score: 0.036
  61. Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997 Feb; 24(1):70-82.
    View in: PubMed
    Score: 0.034
  62. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996 May; 10(5):795-802.
    View in: PubMed
    Score: 0.032
  63. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr; 9(4):628-33.
    View in: PubMed
    Score: 0.030
  64. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am J Hematol. 1993 Aug; 43(4):286-90.
    View in: PubMed
    Score: 0.026
  65. t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes Cancer. 2002 Jun; 34(2):186-92.
    View in: PubMed
    Score: 0.012
  66. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer. 1997 Nov; 20(3):282-91.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.